‘Pharma Bro’ Martin Shkreli wins proxy battle from prison
NY Post
A group of activist investors seeking to wrest control of Martin Shkreli’s pharmaceutical company failed miserably this week — with the “Pharma Bro” voting his shares from prison.
But the battle is not over, and the investors now plan to seize Shkreli’s 44 percent stake in Phoenixus – the parent of Shkreli’s Turing Pharmaceuticals, now renamed Vyera, The Post has learned. On Monday, former Shkreli confidante and Vyera executive Kevin Mulleady, together with Jason Aryeh, a longtime activist investor in the pharmaceutical industry, held a special meeting asking Phoenixus shareholders to replace the current board of directors, who they say are Shkreli cronies.More Related News
How Nvidia co-founder plans to turn Hudson Valley into a tech powerhouse greater than Silicon Valley
A co-founder of chip maker Nvidia is bankrolling a futuristic quantum computer system at Rensselaer Polytechnic Institute – and wants to turn New York’s Hudson Valley into a tech powerhouse.